On Friday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Arena Pharmaceuticals, (NASDAQ:ARNA), Rentech, (NASDAQ:RTK), Tiffany (NYSE:TIF), PRA Health Sciences (NASDAQ:PRAH)
Formerly on March 2 2015 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2014. MS Health estimates that approximately 149,000 prescriptions for BELVIQ were filled in the fourth quarter of 2014, representing growth in total prescriptions of approximately 4% compared to the previous quarter, despite an overall market decline of 4%.
During the fourth quarter of 2014, Eisai recorded net product sales for BELVIQ of $10.0 million. These results reflect the impact of a new savings card launched by Eisai in early 2015 that enables eligible patients without commercial coverage for BELVIQ to pay no more than $75 for each monthly prescription.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s shares picked down -4.19%, and closed at $4.80. The stock volatility for the week is 5.24%, while for the month remained 6.15%. The company holds consensus target price of $7.58.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.28 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -211.10% and Annual EPS growth for the past 5 years is considered as 31.20%.
The mean recommendation of analysts for this stock is 2.70. (Where 1=Buy, 5=Sale).
Arena Pharmaceuticals, Inc. (ARNA) a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults.
On March 17, 2015 Rentech, Inc. (NASDAQ:RTK) disclosed financial and operating results for the three months and year ended December 31, 2014. Keith Forman, President and CEO of Rentech, stated, “2014 was a disappointing year on many fronts, with a number of our businesses and projects underperforming. Our goals for this year are clear: to operate our assets safely; to reduce our net losses; ramp up production at the Canadian pellet plants; to develop a backlog of fibre growth opportunities; and manage costs and improve profits at Fulghum Fibres. We also intend to improve our liquidity, simplify our capital structure, and reduce our overhead costs on a going forward basis.”
Rentech, Inc. (NASDAQ:RTK) declined -4.07%, and closed at $1.18. The company has the market capitalization of $270.72 million. The beta value of the stock is 2.88. On the other hand the stock’s volatility for the week is 7.47%, and for the month is 5.36%. The stock’s price to book ratio is $2.23, however price to sale ratio is $0.57. Analyst’s mean recommendation regarding this stock is 1.30. (Where 1=Buy, 5=Sale).
Rentech, Inc. (RTK) along its subsidiaries provides wood fiber processing services, wood chips, and wood pellets. The company operates through five segments: East Dubuque; Pasadena; Fulghum Fibres; Wood Pellets: Industrial; and Wood Pellets: NEWP. It manufactures and sells natural-gas based nitrogen fertilizer products in North and South America.
On Tiffany & Co. March 20, 2015 Tiffany & Co. (NYSE:TIF) proclaimed its results for the three and 12-month periods (“fourth quarter” and “full year”) ended January 31, 2015. The Company achieved solid growth in worldwide net sales and in net earnings (excluding charges) in the full year, but posted mixed results in the fourth quarter. Management updated its sales and earnings guidance for the year ending January 31, 2016.
Tiffany & Co. (NYSE:TIF) decreased -3.98%, and closed at $82.93. The company holds the market capitalization of $10.72B. For the last twelve months, the stock was able to keep return on equity at 16.80%, while return on assets at 9.70%, in response to its return on investment at 13.70%. Its 20-day moving average decreased -4.38%, below 50-day moving average of -6.39%, below 200-day moving average of -13.93% from the latest market price of $82.93. The mean recommendation of analysts for this stock is 2.30. (Where 1=Buy, 5=Sale).
Tiffany & Co. (TIF) along with its subsidiaries, designs, manufactures, and retails jewelry worldwide. Its jewelry products include fine and solitaire jewelry; engagement rings and wedding bands to brides and grooms; and non-gemstone, sterling silver, gold, and metal jewelry.
PRA Health Sciences Inc (NASDAQ:PRAH) disclosed its financial results for the fourth quarter ended December 31, 2014. For the three months ended December 31, 2014, the Company’s service revenues were $323.8 million, which represents growth of 8%, or $25.0 million, compared to the fourth quarter of 2013 at actual foreign exchange rates. On a constant currency basis, service revenue grew $29.7 million, representing growth of 10% compared to the fourth quarter of 2013. The increase in service revenue is due largely to the increase in our opening backlog, the type of service we are providing on our active studies and the growth in new business awards as a result of higher demand for our services.
PRA Health Sciences Inc (NASDAQ:PRAH) fell -3.95%, and closed at $29.66. and its volatility for the week is 3.61%, while for the month it is 3.65%. The company has the market capitalization of $1.77 billion. The company holds the book value per share of 13.35, whereas cash per share is 1.42. Price to book ratio remained 2.22, while price to sale ratio is 1.22. Analysts mean recommendation for the stock is said to be 1.60 (where 1=Buy, 5=sale).
PRA Health Sciences Inc (PRAH) a contract research organization provides various product development services for pharmaceutical and biotechnology companies worldwide. The company offers integrated services, such as data management, statistical analysis, clinical trial management, and regulatory and drug development consulting.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
